Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LAB 
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: LAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.77
1 Year Target Price $1.77
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.74% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 492.77M USD | Price to earnings Ratio - | 1Y Target Price 1.77 |
Price to earnings Ratio - | 1Y Target Price 1.77 | ||
Volume (30-day avg) 3 | Beta 1.29 | 52 Weeks Range 0.92 - 2.32 | Updated Date 09/14/2025 |
52 Weeks Range 0.92 - 2.32 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -69.95% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -13.62% | Return on Equity (TTM) -29.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 284304681 | Price to Sales(TTM) 2.86 |
Enterprise Value 284304681 | Price to Sales(TTM) 2.86 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 381995008 | Shares Floating 48142055 |
Shares Outstanding 381995008 | Shares Floating 48142055 | ||
Percent Insiders 2.68 | Percent Institutions 72.97 |
Upturn AI SWOT
Standard Biotools Inc
Company Overview
History and Background
Standard Biotools Inc (formerly Fluidigm Corporation), founded in 1999, focused on developing and manufacturing innovative technologies and products for single-cell biology, genomics, and proteomics. Initially, Fluidigm's microfluidic technology was used in agriculture. Eventually, the company pivoted into research. The company went through a restructuring in 2022 and rebranded as Standard Biotools.
Core Business Areas
- Biotechnology Tools: Develops and markets microfluidics-based systems, consumables, and software used in genomics and proteomics research. They are focused on tools for single cell biology.
Leadership and Structure
Standard Biotools is led by a board of directors and an executive management team. The organizational structure is typical of a publicly traded biotechnology company, with departments focused on research and development, manufacturing, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Helios: A CyTOF system used for single-cell protein analysis. Helios competes with instruments from BD Biosciences and Luminex Corporation. Market share data is not publicly available and difficult to accurately estimate; this market is highly competitive and fragmented, dependent on specific applications.
- Biomark HD System: A real-time PCR platform used for gene expression analysis. The Biomark HD competes with instruments from Thermo Fisher Scientific and Bio-Rad Laboratories. Market share data is not publicly available and difficult to accurately estimate; this market is highly competitive and fragmented, dependent on specific applications.
- Advanta Dx SARS-CoV-2 RT-PCR Assay: An assay for detection of SARS-CoV-2. Revenue derived from this product has drastically decreased post-pandemic. Competitors include Roche, Abbott, and Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The biotechnology tools industry is characterized by rapid innovation, intense competition, and high regulatory hurdles. Demand is driven by increasing investments in research and development and advancements in genomic and proteomic technologies.
Positioning
Standard Biotools occupies a niche position focusing on high-throughput and single-cell analysis. Competitive advantages lie in its microfluidic technology and established customer base.
Total Addressable Market (TAM)
The total addressable market for single-cell analysis and related tools is estimated to be in the billions of dollars annually. Standard Biotools holds a smaller portion of this TAM, facing competition from larger, more diversified companies.
Upturn SWOT Analysis
Strengths
- Microfluidic technology expertise
- Established customer base in research institutions
- Focus on single-cell analysis
- Innovative product portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on a niche market
- Past history of inconsistent financial performance
- Restructuring and rebranding process impact
Opportunities
- Expanding applications of single-cell analysis
- Strategic partnerships with larger companies
- Development of new assays and reagents
- Geographic expansion into emerging markets
Threats
- Intense competition from larger companies with greater resources
- Rapid technological advancements rendering existing products obsolete
- Economic downturn impacting research funding
- Regulatory changes affecting product development and approval
Competitors and Market Share
Key Competitors
- TMO
- BIO
- ILMN
- LMNX
Competitive Landscape
Standard Biotools faces intense competition. The company's advantage lies in its specialized technology, but it is outmatched by larger companies in terms of scale and resources.
Major Acquisitions
DVS Sciences
- Year: 2014
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded its capabilities in mass cytometry.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent. Significant change when pivoting from Fluidigm to Standard Biotools
Future Projections: Future growth projections are uncertain and depend on successful execution of its strategy and market conditions. Analyst estimates should be consulted for specific forecasts.
Recent Initiatives: Recent strategic initiatives include focusing on core products, cutting cost and exploring partnerships. Check latest investor presentations.
Summary
Standard Biotools is a company in a highly competitive biotechnology tools market. They have some innovative products, particularly in single-cell analysis. However, they are smaller than their competitors and face financial challenges. Standard Biotools needs to capitalize on market opportunities and manage cost carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice, and you should consult with a qualified professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 814 | Website https://www.standardbio.com |
Full time employees 814 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.